From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.05
First Reported 2009
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 4
Total Number 4
Disease Relevance 0.57
Pain Relevance 0.09

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

nucleoplasm (Apex1) mitochondrion (Apex1) lyase activity (Apex1)
aging (Apex1) endoplasmic reticulum (Apex1) intracellular (Apex1)
Anatomy Link Frequency
brain 1
Apex1 (Mus musculus)
Pain Link Frequency Relevance Heat
Bioavailability 2 94.12 High High
Inflammatory response 4 77.84 Quite High
Inflammation 35 50.00 Quite Low
chemokine 4 47.20 Quite Low
cytokine 3 46.60 Quite Low
Lasting pain 2 44.96 Quite Low
Potency 5 5.00 Very Low Very Low Very Low
Inflammatory marker 4 5.00 Very Low Very Low Very Low
Central nervous system 2 5.00 Very Low Very Low Very Low
midbrain 2 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Encephalitis 2 95.32 Very High Very High Very High
Rabies Virus Infection 6 80.64 Quite High
INFLAMMATION 37 77.84 Quite High
Pulmonary Disease 21 75.84 Quite High
Targeted Disruption 13 65.56 Quite High
Breast Cancer 2 61.92 Quite High
Prion Diseases 32 57.08 Quite High
Pneumonia 7 50.00 Quite Low
Pain 2 44.96 Quite Low
Cancer 4 43.16 Quite Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
In vitro studies showed that D-SPM could partially protect pDNA from degradation by nuclease and exhibited optimal gene transfer efficiency at D-SPM to pDNA weight-mixing ratio of 12.
Protein_catabolism (degradation) of nuclease
1) Confidence 0.05 Published 2010 Journal Journal of Biomedicine and Biotechnology Section Abstract Doc Link PMC2896664 Disease Relevance 0 Pain Relevance 0
Efficient peptide-mediated delivery of siRNA to the brain after iv injection relies on protecting the complex from nuclease and protease degradation en route.
Protein_catabolism (degradation) of nuclease in brain
2) Confidence 0.02 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2885418 Disease Relevance 0.23 Pain Relevance 0
For the most potent AONs, chemistry optimisation was performed by including FANA substitutions in a gapmer configuration in order to improve efficacy and duration of action, as well as to improve resistance to nuclease degradation.
Protein_catabolism (degradation) of nuclease
3) Confidence 0.01 Published 2009 Journal Respir Res Section Body Doc Link PMC2696437 Disease Relevance 0.22 Pain Relevance 0.04
Perhaps excess liposomes encapsulated protease and nuclease-laden serum and fused to LSPCS, degrading them over time, Indeed, 1000 pmol of liposomes nonspecifically delivered LSPCS to cells, indicating that excess liposomes may be fusing with cell membranes, supporting this interpretation.
Protein_catabolism (degrading) of nuclease
4) Confidence 0.01 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2885418 Disease Relevance 0.11 Pain Relevance 0.05

General Comments

This test has worked.

Personal tools